“Lebrikizumab Delivers Clinically Meaningful and Continuous Improvement in Itch-Free Days in Atopic Dermatitis Through One Year”, J of Skin, vol. 7, no. 6, p. s273, Nov. 2023, doi: 10.25251/skin.7.supp.273.